MK-0431A XR in Pediatric Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformain In pediatric subjects with inadequate control on metformin therapy, after 20 weeks: 1. To asses)s the effect of the addition of sitagliptin (MK-0431A XR) compared with the addition of placebo on A1C ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 Infection •To compare MK-5172A to SOF/PR in the treatment of HCV, as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Japanese Children & Adolescents New Onset Fever & Neutropenia To evaluate the safety and tolerability of caspofungin in Japanese pediatric patients.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis as Measured by MRI. Satunnaistettu, kaksoissokkoutettu ja lumekontrolloitu rinnakkaisryhmin etenevä tutkimus, jossa tutkitaan L-000124467 -lääkkeen kliinistä tehoa, turvallissuutta ja siedettävyyttä aaltomaista MS-tautia sairastavilla potilailla MRI menetelmällä a. selvittää L-000124467:n tehoa vähentää hajapesäkkeiden kehittymistä aivoissa verrattuna alkutilaan; b. selvittää L-000124467:n turvallisuutta ja siedettävyyttä;

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy Main objective : In patients with type 2 diabetes mellitus with inadequate glycemic control on metformin therapy at a dose of at least 1500 mg/day: (1) After 52 weeks, to assess the effect of the ad...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II Extension of a Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients with Chronic Kidney Disease who are on Hemodialysis To assess the overall safety and tolerability of intravenous administration of MK-2578 in a 40-week extension study.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma (rrMM) 1. Compare the Progression Free Survival (PFS) as assessed by CAC blinded central review according to the International Myeloma Working Group response criteria, (IMWG criteria) between treatment arms....

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa-2a and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials In patients who have persistent HCV infection after prior participation in a MK-7009 clinical trial: Evaluate the safety and tolerability of MK-7009 600 mg b.i.d. for 48 weeks when used in combination...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients with Homozygous Familial Hypercholesterolemia (HoFH) In adults with HoFH on a stable dose of their regular medications, we wish to evaluate the effects of adding anacetrapib 100 mg for 12 weeks relative to placebo on plasma concentrations of bad cholest...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical trial to test if the drug ertugliflozin is safe and effective when compared to placebo in patients with Type 2 Diabetes whose sugar levels are not well controlled by their current treatment with Metaformin and Sitagliptin After 26 weeks, in subjects with T2DM and inadequate glycemic control on treatment with metformin ≥1500 mg/day and sitagliptin 100 mg q.d.: 1) To assess the A1C-lowering efficacy of the addition of ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune